Comparison of SCH-12679 and Thioridazine in Aggressive Mental Retardates

Abstract

SCH-12679, a benzazepine derivative, was compared to thioridazine and to placebo on the aggressive behaviour of mentally retarded patients. After a three-week chlorpromazine (100 mg t.i.d.) standardizaton period, no significant differences between the three treatment groups were observed in their abnormal behaviour. During the comparative phase, patients treated with SCH-12679 became less hyperative and less agitated while those treated with thioridazine became more violent, more choleric and more provocative. The clinical investigator and the nursing staff found significant differences between the active drugs. As compared to the placebo, SCH-12679 improved the behaviour of the patients while thioridazine aggravated their condition. No important adverse reaction was found and the drugs did not interact with the sex of the patients and the presence of epilepsy. The results suggest that, in mental retardation, physical restraint of hyperactivity might induce aggressivity and that one should be cautious in using neuroleptics in nonpsychotic patients.

Lesch-Nyhan Syndrome: Models, Theories, and Therapies

“…SCH-12679, a D1 receptor antagonist was investigated in non-LNS aggressive individuals [Itil et al, 1972], and its effect was hypothesized to be translatable to LNS patients, but the study was halted due to adverse effects on LNS patients [Albert et al, 1977;Elie et al, 1980]. Fluphenazine, a D1 and D2 receptor antagonist, has shown improvements in self-biting [Goldstein et al, 1985;Jankovic et al, 1988;Gualtieri and Schroeder, 1989], but the use of this drug was again discontinued because of severe side effects of akithesia and tardive dyskinesia [Gualtieri and Schroeder, 1989].…”

Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems

“…Finally, 100 trials were included for review (van Hemert 1975; Albert et al . 1977; Barnes 1977; Elie et al . 1980; Spagnolo et al .…”

Modified Ibogaine Fragments: Synthesis and Preliminary Pharmacological Characterization of 3-Ethyl-5-phenyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]benzothiophenes

“…24 However, the compound was devoid of neuroleptic activity when tested in humans. 25 Following the initial success of SCH12679 (7) in the treatment of aggressive mental retardation, [26][27][28] Elliott et al 29 developed the corresponding 5-phenyl-1,2,3,4,5,6-hexahydroazepino [4,5-b]indoles in an effort to increase the selectivity of this class of fused tricyclic azepines. In mice, these compounds failed to exhibit neuroleptic activity.…”